Tag: esophageal cancer

1. Overall survival at 2 years was 74% for active surveillance and 71% for standard surgery. 2. Median disease-free survival ...

1. Among patients with resectable esophageal cancer, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in improved survival ...

Click here to read this study in NEJM.  ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...

1. Among 234 patients with achalasia, esophageal candidiasis was identified in 12%. 2. Among patients with achalasia, prior esophageal candidiasis, ...

1. Median PFS was 6.6 months in the switch maintenance group and 3.5 months in the control group with HR ...

1. Although capecitabine or XELOX did not improve overall survival when compared to PF, efficacy was comparable suggesting single-agent capecitabine ...

1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. ...

1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. ...

1. Median progression-free survival in zolbetuximab group was greater than in the placebo group (10.6 months vs. 8.7 months). 2. ...

1. For patients aged 70 years and older with esophageal squamous cell carcinoma (ESCC), the combination of simultaneous integrated boost ...